Primary Sjögren's Syndrome Clinical Trial
Official title:
Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome
Primary Sjögren's Syndrome (pSS) is an autoimmune disorder characterized by keratoconjunctivitis sicca and xerostomia. In addition, various extraglandular manifestations may develop. Several immunomodulating agents have been attempted in the treatment of pSS without achieving satisfactory results. Currently, there is no approved systemic treatment for pSS. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that low-dose IL-2 could be a novel therapy in active pSS patients. This clinical study will test the efficacy and safety of low dose IL-2 treatment in pSS. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in pSS. The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for primary Sjögren's Syndrome by randomized controlled study (hrIL-2 (N = 30) versus placebo group (N = 30)).
Each pSS patients (n=60) with Scores>=6 on ESSDAI received low-dose IL-2 or placebo (active group: placebo group =1:1, 1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3 cycles. The end points were safety, clinical and immunologic response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03040583 -
The ASSESS National Multi-center Prospective Cohort
|
||
| Completed |
NCT01989819 -
Primary Sjögren Syndrome
|
||
| Completed |
NCT02291029 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Terminated |
NCT02610543 -
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT04975087 -
The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
|
||
| Completed |
NCT04078386 -
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT05087589 -
Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04212572 -
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
|
||
| Completed |
NCT02149420 -
PD of VAY736 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04858464 -
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
|
||
| Recruiting |
NCT03003572 -
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
|
||
| Completed |
NCT00632866 -
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
|
Phase 3 | |
| Completed |
NCT02334306 -
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT02775916 -
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Terminated |
NCT01552681 -
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT04186871 -
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
| Completed |
NCT00426543 -
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04981145 -
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
|
Phase 4 | |
| Completed |
NCT06432101 -
Acupuncture Combined With Hydroxychloroquine
|
N/A | |
| Completed |
NCT03627065 -
A Study of INCB050465 in Primary Sjögren's Syndrome
|
Phase 2 |